Medline ® Abstracts for References 40-43

of 'Treatment of community-acquired pneumonia in adults who require hospitalization'

40
 
 
US Food and Drug Administration (FDA). FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning. http://www.fda.gov/Drugs/DrugSafety/ucm369580.htm (Accessed on October 09, 2013).
 
no abstract available
41
TI
Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
AU
Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF, Infectious Diseases Society of America
SO
Clin Infect Dis. 2011;52(3):e18.
 
Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures.
AD
Department of Medicine, Division of Infectious Diseases, University of California-San Francisco, San Francisco, California94102, USA. catherine.liu@ucsf.edu
PMID
42
TI
What is the best antimicrobial treatment for severe community-acquired pneumonia (including the role of steroids and statins and other immunomodulatory agents).
AU
Sibila O, Restrepo MI, Anzueto A
SO
Infect Dis Clin North Am. 2013 Mar;27(1):133-47. Epub 2012 Dec 21.
 
Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the United States. The mortality rate due to severe CAP has shown little improvement over the past few years, with a rate as high as 50% mainly in patients admitted to intensive care units. Death and adverse outcomes from CAP result from a complex interplay between the pathogen and the host. Several therapies have been tested in patients with severe CAP in recent years. This article reviews recent data regarding different treatments including antimicrobials and adjunctive therapies in patients with severe CAP.
AD
University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
PMID
43
TI
How important is methicillin-resistant Staphylococcus aureus as a cause of community-acquired pneumonia and what is best antimicrobial therapy?
AU
Wunderink RG
SO
Infect Dis Clin North Am. 2013 Mar;27(1):177-88. Epub 2012 Dec 14.
 
The emergence of methicillin-resistant strains of Staphylococcus aureus has raised issues regarding the importance of methicillin-resistant S aureus (MRSA) in community-acquired pneumonia (CAP) and its optimal treatment. Community-acquired MRSA (CA-MRSA) is an important cause of CAP because of the high mortality if not suspected early, and its occurrence in young patients with long life expectancy. Certain clinical features can increase the probability of CA-MRSA as a cause of CAP. The consistent trend toward better outcomes for documented MRSA pneumonia suggests that linezolid be considered the drug of choice for documented MRSA CAP, especially for CA-MRSA.
AD
Pulmonary and Critical Care Division, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. r-wunderink@northwestern.edu
PMID